Edition:
United States

CymaBay Therapeutics Inc (CBAY.OQ)

CBAY.OQ on NASDAQ Stock Exchange Capital Market

8.16USD
13 Dec 2017
Change (% chg)

-- (--)
Prev Close
$8.16
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
189,973
52-wk High
$9.40
52-wk Low
$1.46

Chart for

About

CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company's product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout. MBX-8025 is a... (more)

Overall

Beta: 2.04
Market Cap(Mil.): $357.93
Shares Outstanding(Mil.): 43.86
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 188.50 15.25
EPS (TTM): -- -- --
ROI: -- -11.67 33.27
ROE: -- -36.21 16.35

BRIEF-CymaBay reports Q3 loss per share $0.21

* CymaBay reports third quarter 2017 financial results and corporate updates

Nov 08 2017

BRIEF-Cymabay to deliver interim results from ongoing phase 2 study of Seladelpar at AASLD 2017

* Cymabay announces oral late-breaking presentation of interim results from an ongoing Phase 2 study of patients with primary biliary cholangitis at the AASLD 2017 Liver Meeting

Oct 09 2017

BRIEF-CymaBay Therapeutics granted EMA orphan drug designation for seladelpar

* CymaBay Therapeutics granted EMA orphan drug designation for seladelpar for the treatment of primary biliary cholangitis Source text for Eikon: Further company coverage:

Sep 11 2017

BRIEF-Cymabay Therapeutics publishes Seladelpar proof-of-concept study

* Cymabay Therapeutics announces the publication of the Seladelpar proof-of-concept study for primary biliary cholangitis in lancet gastroenterology and hepatology

Aug 15 2017

BRIEF-CymaBay Therapeutics reports Q2 loss per share $0.31

* CymaBay reports second quarter 2017 financial results and provides corporate update

Aug 10 2017

BRIEF-CymaBay announces pricing of public offering of common stock

* CymaBay announces pricing of public offering of common stock

Jul 19 2017

BRIEF-Cymabay announces proposed public offering of 10.0 mln common shares

* Cymabay Therapeutics Inc - anticipates using net proceeds from offering to fund ongoing development of seladelpar

Jul 17 2017

BRIEF-CymaBay announces positive interim results from low-dose phase 2 study of seladelpar

* CymaBay announces positive interim results from its ongoing low-dose phase 2 study of seladelpar in patients with primary biliary cholangitis

Jul 17 2017

Earnings vs. Estimates